We are live on ! Find out more
MTCR

Metacrine, Inc. Common Stock

Delisted

MTCR was delisted on the 8th of February, 2023.

29 hedge funds and large institutions have $7.29M invested in Metacrine, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more capital invested

Capital invested by funds: $3.93M → $7.29M (+$3.36M)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

19.2% more ownership

Funds ownership: 19.04%38.24% (+19%)

7% more funds holding

Funds holding: 2729 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

63% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 8

Holders
29
Holders Change
+2
Holders Change %
+7.41%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
3
Reduced
8
Closed
5
Calls
Puts
Net Calls
Net Calls Change

MTCR Hedge Fund Activity: Q4 2022 in Review

29 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Metacrine, Inc. Common Stock (MTCR) for Q4 2022, worth a combined $7.29M — up 86% from $3.93M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new MTCR positions and 5 closed out — a net gain of 2 holders — while 3 added to existing stakes and 8 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $1.05M. The largest seller was CSS LLC, exiting entirely with an estimated $82K sold.

  • 29 institutional investors held Metacrine, Inc. Common Stock (MTCR) as of Q4 2022, up from 27 in Q3 2022.
  • Funds reported $7.29M of Metacrine, Inc. Common Stock stock for Q4 2022, up 86% quarter-over-quarter.
  • 7 funds opened new Metacrine, Inc. Common Stock positions in Q4 2022 and 5 closed out, a net change of +2 holders.
  • The largest Metacrine, Inc. Common Stock buyer in Q4 2022 was Tang Capital Management, an estimated $1.05M added.
  • The largest Metacrine, Inc. Common Stock seller in Q4 2022 was CSS LLC, an estimated $82K sold.

Based on aggregated 13F filings for Q4 2022.